354 Stock Chart & Stats
€22.20
-€0.20(-0.64%)
At close: 4:00 PM EDT
€22.20
-€0.20(-0.64%)
Day’s Range― - ―
52-Week Range€19.40 - €42.00
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
€639.22M
Enterprise Value€2.24K
Total Cash (Recent Filing)€129.47M
Total Debt (Recent Filing)€857.79M
Price to Earnings (P/E)14.9
Beta0.70
Next Earnings
Nov 05, 2026EPS Estimate
1.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.53
Shares Outstanding32,555,614
10 Day Avg. Volume12
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio-3.13
Price to Book (P/B)4.87
Price to Sales (P/S)1.88
P/FCF Ratio4.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€41.86Price Target Upside88.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)6.41
Revenue Forecast (FY)€718.89M
Bulls Say, Bears Say
Bulls Say
ADHD Franchise GrowthThe ADHD portfolio is showing strong commercial traction, with accelerating Jornay PM growth and an acquired Azstarys product already contributing revenue. Azstarys’ stated IP protection through 2037 supports a potentially durable platform for expansion, sales-force leverage, and recurring prescription growth.
Strong Cash GenerationOperating and free cash flow remain closely aligned and consistently robust, indicating that reported earnings are substantially supported by cash generation. This provides Collegium with internal funding capacity for debt reduction, commercial investment, acquisitions, and other capital-allocation priorities over the coming quarters.
Belbuca Market AccessBelbuca combines demonstrated year-over-year growth with broader payer access, expanding the addressable patient base and improving potential prescription availability. Additional formulary coverage can support recurring demand and help sustain the pain portfolio even as other branded opioid products face pressure.
Bears Say
Elevated LeverageCollegium’s debt remains large relative to its equity base, leaving the company more sensitive to earnings variability, refinancing conditions, and post-acquisition execution. Although leverage improved from prior periods, the capital structure can still constrain financial flexibility and compete with growth investment for cash.
NUCYNTA Pricing PressureThe NUCYNTA decline reflects a structural reduction in net realizations from authorized-generic agreements rather than a temporary reporting fluctuation. Lower pricing can persistently reduce the franchise’s revenue and profit contribution, increasing the growth burden on ADHD products and the remaining pain portfolio.
Belbuca Loss-of-exclusivity RiskA potential generic launch creates a defined medium-term threat to Belbuca’s pricing, market share, and contribution to the pain portfolio. Because Belbuca is currently growing and gaining formulary access, loss of exclusivity could undermine an important offset to declines elsewhere in branded opioids.
Collegium Pharmaceutical News
354 FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was €19.40 and its highest was €42.00 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is €639.22M.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Nov 05, 2026 which is in 52 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Aug 06, 2026. The company reported €1.651 earnings per share for the quarter, beating the consensus estimate of €1.478 by €0.173.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 1.57.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 32,555,614 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of €1.651 in its last earnings report, beating expectations of €1.478. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in DE:354
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Collegium Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€41.86 (88.55% Upside)
€41.86 (88.55% Upside)
Blogger Sentiment
Bullish
DE:354 Sentiment 100%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
34.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
354 Company Deck
354 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong, accelerating growth in the ADHD franchise—Jornay PM momentum, the strategic Azstarys acquisition with early revenue and raised guidance, Belbuca growth and incremental formulary wins, and an 8% increase in adjusted EBITDA. Offsetting these positives were meaningful declines in the NUCYNTA franchise driven by authorized generic pricing, a decline in Xtampza ER, a GAAP net loss driven by acquisition-related costs, substantial cash deployed to acquire Azstarys and a modest leverage increase, and potential LOE risk for Belbuca. Overall, management presented a constructive outlook focused on ADHD-led growth and disciplined capital deployment while acknowledging near-term pain portfolio pressures and one-time acquisition impacts.View all DE:354 earnings summaries354 Stock 12 Month Forecast
Average Price Target
€41.86
▲(88.55% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Indivior
―
Amneal Pharmaceuticals
―
Aquestive Therapeutics
―